RIGEL PHARMACEUTICALS INC Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Rigel Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Rigel Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $12.4M.
  • Rigel Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $3.88M.
  • Rigel Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$25.1M, a 57.2% increase from 2022.
  • Rigel Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$58.6M, a 227% decline from 2021.
  • Rigel Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$17.9M, a 39.8% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$25.1M +$33.5M +57.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 -$58.6M -$40.7M -227% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$17.9M +$11.8M +39.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-05
2020 -$29.7M +$37.2M +55.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
2019 -$66.9M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.